Instructions for Celista oral solution 0.1 mg/ml bottle 100 ml
Composition
active ingredient: miramistin;
1 ml of solution contains 0.1 mg of miramistin;
Excipients: purified water.
Dosage form
Oral solution.
Main physicochemical properties: colorless or with a yellowish tinge, transparent liquid that foams when shaken.
Pharmacotherapeutic group
Antiseptics and disinfectants. ATX code D08A J.
Pharmacological properties
Pharmacodynamics
The action of Miramistin is based on the direct hydrophobic interaction of the molecule with the lipids of the membranes of microorganisms, which leads to their fragmentation and destruction. At the same time, part of the Miramistin molecule, immersing in the hydrophobic area of the membrane, destroys the supramembrane layer, loosens the membrane, increases its permeability for high-molecular substances, changes the enzymatic activity of the microbial cell, inhibiting enzyme systems, which leads to the suppression of the vital activity of microorganisms and their cytolysis.
Unlike other antiseptics, Miramistin has a high selectivity of action against microorganisms, since it has almost no effect on the membranes of human cells. This effect is associated with a different structure of human cell membranes (a significantly longer length of lipid radicals, which sharply limits the possibility of hydrophobic interaction of Miramistin with cells).
Miramistin has a pronounced antimicrobial effect against gram-positive and gram-negative, aerobic and anaerobic, spore-forming and asporogenic bacteria in the form of monocultures and microbial associations, including hospital strains.
It has an antifungal effect on ascomycetes of the genus Aspergillus and the genus Penicillium, yeast (Rhodotorula rubra, Torulopsis gabrata) and yeast-like (Candida albicans, Candida tropicalis, Candida krusei) fungi, dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton schoenleini, Trichophyton violaceum, Epidermophyton Kaufman-Wolf, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis), as well as other pathogenic fungi (for example, Pityrosporum orbiculare (Malassezia furfur)) in the form of monocultures and microbial associations. Under the action of Miramistin, the resistance of microorganisms to antibiotics decreases.
Pharmacokinetics
When applied topically, it is not absorbed through the skin and mucous membranes.
Indication
Comprehensive treatment of acute and chronic tonsillitis; comprehensive treatment of candidiasis of the oral mucosa; treatment of periodontitis, stomatitis, gingivitis, periodontitis; hygienic treatment of removable dentures; prevention of microbial complications after surgical interventions on the oral mucosa.
Contraindication
Individual sensitivity to Miramistin.
Interaction with other medicinal products and other types of interactions
With the simultaneous use of antibiotics with Miramistin, a decrease in the resistance of microorganisms to antibiotics is observed.
Ability to influence reaction speed when driving vehicles or other mechanisms
The use of the drug is characterized by the absence of any effect on the ability to drive vehicles and engage in other potentially dangerous activities that require increased concentration and speed of psychomotor reactions.
Use during pregnancy or breastfeeding
Since the drug is almost completely absorbed, Celista® can be used during pregnancy or breastfeeding.
Method of administration and doses
Apply topically to adults.
When treating tonsillitis, gargle with Celista® solution 3-4 times a day. The amount of medicine per rinse is 10-15 ml.
Treatment of candidiasis of the oral mucosa should be carried out by rinsing 2–4 times a day. The amount of the drug per rinse is 10–15 ml.
When treating stomatitis, gingivitis, and periodontitis, rinse the oral cavity with Celista® solution 3–4 times a day. The amount of the drug per rinse is 10–15 ml.
In the treatment of periodontitis, Miramistin solution is injected into periodontal pockets on turundas with subsequent applications to the gums for 15 minutes. In case of exacerbations, rinse the periodontal pockets with Celista® using a syringe and insert turundas with the drug into the abscess cavity. After vestibuloplasty and frenulectomy, the drug is used in the form of baths in outpatient settings. For the purpose of hygienic treatment of removable dentures, leave the latter overnight in Miramistin solution, before using the dentures, rinse thoroughly with running water.
Children
Since there is not sufficient experience in using Miramistin solution for the treatment of children, it should not be used in pediatric practice.
Overdose
Overdose phenomena were not observed.
Adverse reactions
Immune system disorders: hypersensitivity reactions.
Other: in some cases, a short-term burning sensation may occur, which disappears on its own after 15–20 seconds and does not require discontinuation of the drug.
Expiration date
3 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ° C. Do not freeze. Keep out of the reach of children.
Packaging
100 ml in a bottle; 1 bottle with a measuring cup in a pack.
Vacation category
Without a prescription.
Producer
PrJSC "Pharmaceutical Company "Darnitsa".
Location of the manufacturer and its business address
Ukraine, 02093, Kyiv, Boryspilska St., 13.
